<DOC>
	<DOCNO>NCT03011450</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety K-877 adult patient With Fasting High Triglyceride Levels ≥500 mg/dL &lt; 2000 mg/dL Mild Moderate Renal Impairment .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety K-877 Adult Patients With Fasting High Triglyceride Levels Mild Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Able understand willing comply study requirement procedures throughout duration study give write informed consent ; Aged ≥18 year ; Patients receive statin therapy must meet one follow criterion : Aged ≥21 year clinical atherosclerotic cardiovascular disease ( ASCVD ) ( history acute coronary syndrome myocardial infarction , stable unstable angina , coronary revascularization , stroke , transient ischemic attack [ TIA ] presume atherosclerotic origin , peripheral arterial disease revascularization ) , highintensity statin ( moderateintensity statin candidate highintensity statin due safety concern ) ; Aged ≥21 year history LDLC ≥190 mg/dL , due secondary modifiable cause , highintensity statin ( moderateintensity statin candidate highintensity statin due safety concern ) ; Aged 40 75 year , inclusive , without clinical ASCVD diabetes history LDLC 70 189 mg/dL , inclusive , moderate highintensity statin ; Aged 40 75 year , inclusive , without clinical ASCVD diabetes , history LDLC 70 189 mg/dL , inclusive , estimate 10year risk ASCVD ≥7.5 % Pooled Cohort Equation moderate highintensity statin ; Patients currently statins , must meet criterion statin therapy list ; Fasting TG level ≥500 mg/dL ( 5.65 mmol/L ) &lt; 2000 mg/dL ( 22.60 mmol/L ) base mean Visit 2 ( Week 2 ) Visit 3 ( Week 1 ) . Mild moderate renal impairment eGFR &gt; = 30mL/min/1.73 &lt; 90 mL/min/1.73 Visit 1 Patients require lipidaltering treatment study drug ( K877 fenofibrate ) , statins , ezetimibe , PCSK9 inhibitor course study . These include bile acid sequestrants , nonstudy fibrates , niacin ( &gt; 100 mg/day ) , omega3 fatty acid ( &gt; 1000 mg/day ) , supplement use alter lipid metabolism include , limited , red rice yeast supplement , garlic supplement , soy isoflavone supplement , sterol/stanol product , policosanols ; Body mass index ( BMI ) &gt; 45 kg/m2 Visit 1 ( Week 8 Week 6 ) ; Patients type 1 diabetes mellitus ; Patients newly diagnose ( within 3 month prior Visit 2 [ Week 2 ] ) poorly control type 2 diabetes mellitus ( T2DM ) , define hemoglobin A1c &gt; 9.5 % Visit 1 ( Week 8 Week 6 ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>